Merck & Company will begin funding cto resolve state and federal claims over its painkiller Vioxx. The first payment of $500 million is scheduled for August 6; additional payments will follow. Merck said it met its threshold to make these payouts and waived its right to walk away from last November’s agreement to settle roughly [...]
Continue reading...27. July 2008
Arthritis drug Vioxx (Rofecoxib) has been voluntarily recalled by Merck & Co Inc. worldwide. The move to pull the COX-2 inhibitor off the market on September 30, 2004 shocked the arthritis world and rocked the stock value of Merck. The Reason The decision to recall Vioxx followed a three year trial, known as APPROVe (Adenomatous Polyp Prevention on [...]
Continue reading...27. July 2008
Arthritis drug Vioxx (Rofecoxib) was recalled by Merck & Co., Inc. The Vioxx recall was voluntarily started by Merck to discontinue the COX-2 inhibitor in September, 2004. Person’s affected by the Vioxx side effects are urged to seek medical and legal help. The Vioxx Recall was prompted after a three year trial known as Adenomatous Polyp [...]
Continue reading...8. July 2008
Merck & Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib) from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events (including heart attack and stroke) in patients on Vioxx. Vioxx is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 [...]
Continue reading...
27. July 2008
0 Comments